Robert Bettigole, founder and managing partner of Elm Street Ventures. See sector focus and contact routes.
Robert Bettigole, founder and managing partner of Elm Street Ventures, invests primarily at the seed and early stages in life sciences (therapeutics, diagnostics, medical devices) and green/information technology, with initial checks of $500,000–$1 million and follow-ons up to $2.5 million. His distinctive thesis centers on backing Yale faculty and technology licensed from Yale, as Yale is the firm’s largest investor and the primary source of deals. Notable portfolio companies include Arvinas (his firm’s biggest success story, which raised a $15M Series A co-led by Elm Street), P2 Science (where he is chairman), Halda Therapeutics, Allyx Therapeutics, and CellFE. Approximately 70% of Elm Street’s investments target life sciences, while 30% focus on green tech, IT, and other sectors.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in New Haven when building a target list.
Investors like Robert Bettigole · Full investor directory · Investor access · Company funding database